The suppression of pathological angiogenesis, which is principally driven by vascular endothelial growth factors (VEGF) and by their interaction with the receptors VEGFR1 and VEGFR2, set on the surface of endothelial cells [34], is indeed an efficient and clinically validated approach in cancer therapy. Here, VEGFA is linked to cancer.